Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | KLK1 | P06870 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3515711 | 0.78 | CTSB (0.46) | PIK3CAPIK3CBPIK3CDCYP3A4KDM4E | |
| SCHEMBL3516034 | 0.78 | AURKA (0.43) | PIK3CAPIK3CBPIK3CDKDM4E | |
| SCHEMBL3515736 | 0.78 | ACP1 (0.47) | KDM4E | |
| SCHEMBL3515097 | 0.75 | SMN1; SMN2 (0.48) | CYP3A4KDM4EUSP2KMT2A | |
| SCHEMBL3516223 | 0.73 | BACE1 (0.49) | KDM4E | |
| SCHEMBL3514710 | 0.72 | P2RX7 (0.44) | CYP3A4KDM4E | |
| SCHEMBL3517421 | 0.72 | ADRA2C (0.43) | MEN1KMT2A | |
| SCHEMBL3519288 | 0.70 | HDAC3 (0.44) | KDM4E | |
| SCHEMBL3538616 | 0.70 | KMT2A (0.46) | CYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL3518012 | 0.69 | SCN1A (0.44) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | RNASEH1, RNASE1, RNASEL | PIK3CA 2050/4885PIK3CB 3326/4885PIK3CD 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.